title: Influence of acid suppressants on gastric emptying: cross-over analysis in healthy volunteers.
abstract: BACKGROUND
  Gastric emptying plays an important role in gastroesophageal reflux disease. Acid suppressants such as H2 receptor antagonists and/or proton pump inhibitors are often used in patients with gastroesophageal reflux disease. However, it remains controversial whether H2 receptor antagonists and proton pump inhibitors delay or accelerate gastric emptying. Here, the influence of acid suppressants on gastric emptying was evaluated via a cross-over study using the [13C]-labeled acetate breath test.
  
  
  METHODS
  Twenty normal male subjects without gastroesophageal reflux disease symptoms were enrolled. Gastric emptying was investigated five times in every subject by the [13C]-labeled acetate breath test with oral administration of the vehicle, domperidone, and three acid suppressants: ranitidine, famotidine and rabeprazole. Gastric emptying was estimated by the values of T(max-calc), T(1/2) and %dose/2 h calculated from the 13CO2 breath excretion curve.
  
  
  RESULTS
  Using the T(max-calc) values, rabeprazole, ranitidine and famotidine did not influence gastric emptying time in comparison with vehicle administration. Using the T(1/2) and %dose/2 h values, rabeprazole tended to delay gastric emptying. Domperidone produced a statistically significant acceleration of gastric emptying for all three variables (P < 0.05).
  
  
  CONCLUSIONS
  Oral dosage of the H2 receptor antagonists, ranitidine and famotidine, has no significant effect on gastric emptying. However, rabeprazole may delay gastric emptying more strongly than H2 receptor antagonists.
authors.affiliation: Department of Gastroenterology and Hepatology, School of Medicine, Shimane University, Izumo-shi, Shimane, Japan.
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Amano
authors.forename: Takafumi
authors.initials: T
authors.lastname: Yuki
authors.forename: Takayuki
authors.initials: T
authors.lastname: Ose
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyake
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Kushiyama
authors.forename: Shuichi
authors.initials: S
authors.lastname: Sato
authors.forename: Shunji
authors.initials: S
authors.lastname: Ishihara
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kinoshita
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000284:Administration, Oral; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001944:Breath Tests; D018592:Cross-Over Studies; D004294:Domperidone / Q000008:administration & dosage; D018492:Dopamine Antagonists / Q000008:administration & dosage; D015738:Famotidine / Q000008:administration & dosage*; D005746:Gastric Emptying / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D064750:Rabeprazole; D011899:Ranitidine / Q000008:administration & dosage*; D018709:Statistics, Nonparametric
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D018492:Dopamine Antagonists; D064750:Rabeprazole; D004294:Domperidone; D015738:Famotidine; D011899:Ranitidine